Bactericidal activity of the new 4-quinolones DU-6859a and DV-7751a

References

1. Sato K., Hoshino K., Tanaka M., Hayakawa I., Osada Y. Antimicrobial activity of DU-6859, a new potent fluoroquinolone, against clinical isolates. Antimicrob Agents Chemother 1992; 36:1491–1498
   [Google Scholar]
2. Tanaka M., Hoshino K., Ishida H., Sato K., Hayakawa I., Osada Y. Antimicrobial activity of DV-7751a, a new fluoroquinolone. Antimicrob Agents Chemother 1993; 37:2112–2118
   [Google Scholar]
3. Morrissey I., Smith J. T. The activity of 4-quinolones against Pseudomonas aeruginosa. Arzneim-Forsch/Drug Res 1994; 44:1157–1161
   [Google Scholar]
4. Lewin C. S., Morrissey I., Smith J. T. The mode of action of quinolones: the paradox in activity of low and high concentrations and activity in the anaerobic environment. Eur J Clin Microbiol Infect Dis 1991; 10:240–248
   [Google Scholar]
5. Ratcliflfe N. T., Smith J. T. Ciprofloxacin and ofloxacin exhibit a rifampicin-resistant bactericidal mechanism not detectable in other 4-quinolone antibacterial agents. J Pharm Pharmacol 1984; 36: Suppl 59P
   [Google Scholar]
6. Lewin C. S., Amyes S. G. B., Smith J. T. Bactericidal activity of enoxacin and lomefloxacin against Escherichia coli KL16. Eur J Clin Microbiol Infect Dis 1989; 8:731–733
   [Google Scholar]
7. Lewin C. S., Amyes S. G. B. The bactericidal activity of DR-3355, an optically active isomer of ofloxacin. J Med Microbiol 1989; 30:227–2318
   [Google Scholar]
8. Lewin C. S., Amyes S. G. B. Conditions required for the bactericidal activity of fleroxacin and pefloxacin against Escherichia coli K L16. J. Med Microbiol 1990; 32:83–86
   [Google Scholar]
9. Lewin C. S. Antibacterial activity of a 1,8-naphthyridine quinolone, PD131628. J Med Microbiol 1992; 36:353–357
   [Google Scholar]
10. Lewin C. S., Morrissey I., Smith J. T. The bactericidal activity of sparfloxacin. J Antimicrob Chemother 1992; 30:625–632
    [Google Scholar]
11. Lewin C. S., Amyes S. G. B. Bactericidal action of PD 127, 391, an enhanced spectrum quinolone. J Med Microbiol 1990; 33:67–70
    [Google Scholar]
12. Ratcliffe N. T., Smith J. T. Norfloxacin has a novel bactericidal mechanism unrelated to that of other 4-quinolones. J Pharm Pharmacol 1985; 37: Suppl 92P
    [Google Scholar]
13. Lewin C. S., Smith J. T. Bactericidal mechanisms of ofloxacin. J Antimicrob Chemother 1988; 22: Suppl C 1–8
    [Google Scholar]
14. Morrissey I., Smith J. T. Activity of quinolone antibacterials against Streptococcus pneumoniae. Drugs 1993; 45: Suppl 3196–197
    [Google Scholar]
15. Lewin C. S., Morrissey I., Smith J. T. The fluoroquinolones exert areduced rate of kill against Enterococcus faecalis. J Pharm Pharmacol 1991; 43:492–494
    [Google Scholar]
16. Smith J. T. Awakening the slumbering potential of the 4-quinolone antibacterials. Pharm J 1984; 233:299–305
    [Google Scholar]
17. Knox R., Smith J. T. The nature of penicillin resistance in staphylococci. Lancet 1961; 2:520–522
    [Google Scholar]
18. Smith J. T. Mutation rates to 4-quinolone resistance. ArzneimittelForschung Res 1990; 40:65–68
    [Google Scholar]
19. Morrissey I., Khatri N., Leighton H., Mustafa N., Nathan C., Smith J. T. The interaction between the 4-quinolone S(–)-ofloxacin and other antibacterials against Streptococcus pneumoniae. J Pharm Pharmacol 1992; 44: Suppl 1057
    [Google Scholar]
20. Piddock L. J. V. New quinolones and gram-positive bacteria. Antimicrob Agents Chemother 1994; 38:163–169
    [Google Scholar]